Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. - Wikidata - wikimedia - TriplyDB

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

http://www.wikidata.org/entity/Q34524632

about

High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma Positron emission tomography (PET)-adapted therapy for Hodgkin lymphoma patients High-dose chemotherapy followed by autologous stem cell transplantation for refractory/relapsed Hodgkin lymphoma patients Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma Fifty years of melphalan use in hematopoietic stem cell transplantation Customized targeted therapy in Hodgkin lymphoma: hype or hope?Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant Advances in the treatment of relapsed or refractory Hodgkin's lymphoma Pembrolizumab in classical Hodgkin's lymphoma Lung cancer and concurrent or sequential lymphoma: Two case reports with hypersensitivity to bevacizumab and a review of the literature Hodgkin lymphoma, version 2.2015.Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population-based cancer registry data in Japan from 1993 to 2006.Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.Hodgkin's lymphoma in adults: diagnosis, treatment and follow-up.GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma.ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma.Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.Hodgkin's lymphoma therapy: past, present, and future.A Historical Tale of Two Lymphomas: Part I: Hodgkin lymphoma Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention.Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography.Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.

P2860

Q24201885-6A8CCFDF-E538-48E8-B17B-AE61A72956C5 Q24202622-6BB0A7C0-B38B-4D42-88AC-4BE100522C19 Q24235563-B4E54E84-A6D0-47B8-AE8A-9B6883B27214 Q24633761-21E9C493-36BB-43E2-B6A0-5B8FDA3402D0 Q26765151-8439C9A2-DECB-40D1-8B72-C6F18BE817C9 Q26770716-55DF080C-EFD3-466B-A769-78705B521EB2 Q26822480-C2022E14-0471-48EE-A071-F84048B5203A Q26824498-178ECA42-350B-428E-A9AF-44BE4BD4657C Q27002554-154B1FF3-ACA9-4365-932A-A06B20D583FF Q27011510-2CACCA40-508C-40BF-B046-EBEC925EC558 Q27022992-28008B14-E6EF-4325-989A-DF00FE67A3DF Q27694504-C9C4D0D6-2015-47E8-A078-004111A18986 Q28079273-1B9FF25E-6F41-4653-991A-2CBA7C93F460 Q28386127-171C68F2-8EB8-4281-9DE0-0BB01707BF1E Q30769157-2BD737EC-A079-4B70-89BD-68CD0BC2AF18 Q30895580-3A0AE8A1-3A03-4A7C-A41F-D83F6F3D76D1 Q33347071-4A726290-41ED-4DD6-9EFD-7590D37DF38D Q33365711-0EEE1F9D-1016-4F86-96DF-ADFD0AC3D587 Q33379431-5A0A3713-9A72-4132-81B1-EAAC048BE4A4 Q33384057-FE8EC862-30C6-408E-850C-D27B2A508DBC Q33400803-4CB7132C-B3EC-4A10-914B-5F7C91343E7F Q33405357-D58C0264-C5B8-493C-A85C-AD60AB2DC1B7 Q33406827-9D466D0F-DEAB-49C6-B6D9-C26BA43F3CC4 Q33411127-F56E112E-ABAD-4A6B-BBAC-1142E81639EE Q33418817-5EFEB76F-7D65-4B79-808A-9B6B2F45C601 Q33432027-0A49C2D3-783A-45D5-87F7-FD1292D9593F Q33652742-6F71FCD3-5AA2-4318-BFAC-32F163F78568 Q33704061-DBF745C2-8E41-4F3B-9EE9-9ED6C9B4BF2A Q33828956-D75BD535-054F-4908-BF93-813EE0D2B9C6 Q33886267-BA8477B0-64E5-48A1-8817-8E11AB009E15 Q34064220-63336DD5-E6E6-4BAC-A8AF-CDCC8BF70A19 Q34089534-3BA7D390-F0ED-4939-997B-33FFC885A972 Q34095620-F32B1797-1ECF-40B4-8BA2-FB1C66BAD58D Q34115831-D4E7BA13-8A53-4C5E-80B2-7112DC6CE358 Q34240314-1D03200F-959A-41A4-8BE8-0301A249D731 Q34296914-BBADA318-3957-4CDE-94E1-5D52498258F2 Q34479660-F9D5013E-798B-49D9-99EA-450217D0E78F Q34490998-C3E7E172-D626-4DC9-9F2E-69FAE0B5C804 Q34495333-8DF299F8-E44C-4C28-AB3E-DAB9CBB6F320 Q34545371-9BFC7A0B-17FA-4362-8E14-EFDB6B66700D

P2860

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

http://www.wikidata.org/entity/Q34524632

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Aggressive conventional chemot ...... s disease: a randomised trial.

@ast

Aggressive conventional chemot ...... s disease: a randomised trial.

@en

Aggressive conventional chemot ...... s disease: a randomised trial.

@nl

type

label

Aggressive conventional chemot ...... s disease: a randomised trial.

@ast

Aggressive conventional chemot ...... s disease: a randomised trial.

@en

Aggressive conventional chemot ...... s disease: a randomised trial.

@nl

prefLabel

Aggressive conventional chemot ...... s disease: a randomised trial.

@ast

Aggressive conventional chemot ...... s disease: a randomised trial.

@en

Aggressive conventional chemot ...... s disease: a randomised trial.

@nl

P1433

Q34524632-E40454B3-D606-4090-91EA-2DA562ED0251

P1476

Q34524632-5CF51C9C-7540-4425-94A9-E81F9EB28930

P2093

Q34524632-04EC5963-2912-4F09-8377-5A53D29E0BBD

Q34524632-090FE48F-8E9B-4922-91FB-695E5011E27F

Q34524632-150CE64C-3BEA-430C-861C-F87E46DF867F

Q34524632-1CDEA688-6936-4942-92AA-9602A2536C62

Q34524632-216A2095-C58B-45FD-A74A-A559FBF8251E

Q34524632-37C47347-B83C-40C2-8468-8C7A8E9E0D83

Q34524632-47B19C46-915D-42C1-83BC-CBB08702B605

Q34524632-6E1607A1-35FB-4828-9309-9D0511EB778C

Q34524632-70080FC2-899A-48E0-A63F-987AFACC703D

Q34524632-879EBF57-88E8-4A7C-871C-911D0D3FCEFA

P304

Q34524632-82C9EDDF-E289-47C4-8AEE-B110D4F6BC4F

P31

Q34524632-42FB14DA-BE21-4987-9FF1-E9897E25D76B

P356

Q34524632-28C2A212-2F6E-41C0-AF65-AAB2141220E0

P407

Q34524632-34559BA5-FD71-4D23-AE73-B5425D90C258

P433

Q34524632-25393EA5-4544-402E-B1D6-02F430442C98

P478

Q34524632-11F06956-BA56-458C-A5AB-0631A3BF3EBC

P50

Q34524632-171FC0AE-4AB4-471C-86E1-B8BD17274A8F

P577

Q34524632-F29FC9B4-D3BE-4DC7-8192-F4E4FD34E6EB

P698

Q34524632-212BC8BD-B060-491C-BE96-CBB1D23220C4

P921

Q34524632-FD47B7DE-B09E-4995-9D3E-2460019588D4

P356

S0140-6736(02)08938-9

P1433

P1476

Aggressive conventional chemot ...... s disease: a randomised trial.

@en

P2093

Andreas Lohri

http://www.w3.org/2001/XMLSchema#string

Angelo M Carella

http://www.w3.org/2001/XMLSchema#string

Anthony H Goldstone

http://www.w3.org/2001/XMLSchema#string

Beate Pfistner

http://www.w3.org/2001/XMLSchema#string

Bettina Koch

http://www.w3.org/2001/XMLSchema#string

Friederike Boissevain

http://www.w3.org/2001/XMLSchema#string

German Hodgkin's Lymphoma Study Group

http://www.w3.org/2001/XMLSchema#string

Hartmut Kirchner

http://www.w3.org/2001/XMLSchema#string

Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

http://www.w3.org/2001/XMLSchema#string

Markus Sieber

http://www.w3.org/2001/XMLSchema#string

P304

2065-2071

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(02)08938-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

9323

http://www.w3.org/2001/XMLSchema#string

P478

359

http://www.w3.org/2001/XMLSchema#string

P50

Dirk Hasenclever

P577

2002-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12086759

http://www.w3.org/2001/XMLSchema#string

P921